Pharmafile Logo
Pharmafocus logo
Advanced Search

EMA

Showing 15 posts of 400 posts found.

top_ten

Top Ten most popular articles on Pharmafile.com this week

March 2, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines

We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …

News
satu1028-pano_1024_px

EMA set to also revise guidelines of Alzheimer’s trials

February 28, 2018
Medical Communications Alzheimer's, EMA, FDA, biotech, drugs, pharma, pharmaceutical

The EMA, following on from the FDA’s lead earlier this month, has announced that it will revise its guidelines on …

News

Novo’s Ozempic secures European approval in type 2 diabetes

February 12, 2018
Sales and Marketing EC, EMA, Europe, Novo Nordisk, diabetes, pharma

Novo Nordisk has revealed that its drug Ozempic (semaglutide) has received approval from the European Commission (EC) as a monotherapy …

News
online_feature_image

New Year, new goals

February 8, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CRUK, Cancer Research UK, Chiesi, EMA, FDA, Genetic Alliance, pharma

With the New Year begun in earnest, Pharmafocus speaks to a range of players in pharma and the life sciences …

Feature
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 2, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Alzheimer's, Apotex, AstraZeneca, Brexit Health Alliance, CDC, Duchenne Muscular Dystrophy, EMA, Italy, Sanofi, amazon, brexit, santhera, top ten

It’s the first Friday of February, and it’s time for another recap of the top ten articles most popular with …

News
amsterdam-1910176_960_720

Italy refuses to give up hope on EMA HQ

January 30, 2018
Medical Communications, Research and Development EMA, amsterdam, biotech, drugs, pharma, pharmaceutical

It is no secret that Milan was not best pleased that it was pipped to the post to host the …

News
accesstoraxone

Santhera’s Raxone rejected in Europe for Duchenne muscular dystrophy

January 29, 2018
Sales and Marketing Duchenne Muscular Dystrophy, EMA, Europe Santhera, pharma

While the EMA’s Committee for Medicinal products for Human Use (CHMP) recommended a spree of treatments over the past week, …

News
novartis_outside_1

Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US

January 17, 2018
Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma

Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …

News
4420456374_64a3d7e6aa

Pharmafile.com’s top ten stories of 2017

December 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit

After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …

News
samsung_bioepis

Samsung Bioepis’ Ontruzant becomes first Herceptin biosimilar approved in Europe

November 20, 2017
Sales and Marketing EMA, Herceptin, Roche, Samsung Bioepis

Samsung Bioepis has announced that Ontruzant, the company’s biosimilar version of Roche’s Herceptin, has been awarded marketing authorisation in Europe …

News
1707_eu-agencies_relocations_website

EMA Headquarters: There’s no place like home

November 13, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, biotech, brexit, drugs, pharma, pharmaceutical

With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 …

Feature

MSD withdraws European application of Keytruda combo in lung cancer

October 30, 2017
Sales and Marketing EMA, MSD, keytruda

MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as …

News
pharmafocus_november_2017_front_page

The November 2017 issue of Pharmafocus is now live!

October 23, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR-T, EMA, NHS, Pharmafocus, Trump, brexit, clinical trial transparency, pharma

The November edition of Pharmafocus is now live and available to read online here!

News

EMA responds to criticism of its cancer drug approvals

October 17, 2017
Manufacturing and Production, Medical Communications Cancer, EMA, biotech, drugs, oncology, pharma, pharmaceutical

The EMA received a broadside just less than two week ago from a group of researchers that had studied data …

News
ema_interior

57% of cancer drugs uses approved by EMA show no benefit

October 5, 2017
Sales and Marketing EMA, biotech, drugs, oncology, pharma, pharmaceutical

A new study conducted by King’s College London and LSE has found that of 48 treatments approved between 2009 and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025